BBS-Bioactive Bone aktie (BONEH)

BBS-Bioactive Bone Substitutes Oyj hakee osakkeidensa poistamista Nasdaq First North -listalta

MFN • 05 Mar 13:30

BBS-Bioactive Bone Substitutes Oyj: Taloudellinen tiedottaminen ja konkurssi

MFN • 20 Feb 20:00

BBS-Bioactive Bone Substitutes Oyj - Sisäpiiritieto: BBS-Bioactive Bone Substitutes Oyj on asetettu konkurssiin

MFN • 17 Feb 12:15

BBS-Bioactive Bone Substitutes Plc - Insider information: BBS-Bioactive Bone Substitutes Plc Files for Bankruptcy

MFN • 12 Feb 16:00

BBS-Bioactive Bone Substitutes Oyj: Tilannetietoa yhtiön rahoitustilanteen ja toiminnan turvaamiseksi tehtävistä toimenpiteistä

MFN • 10 Feb 08:00

BBS-Bioactive Bone Substitutes Oyj: Talouspäällikkö Annastiina Kauppinen on irtisanoutunut yhtiön palveluksesta

MFN • 06 Feb 14:00

BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one former member of Company’s Board of Directors

BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one forme...

MFN • 31 Jan 15:30

Korjaus: BBS-Bioactive Bone Substitutes Oyj – Sisäpiiritieto: Toimitusjohtaja Juliusz Rakowski on irtisanonut toimitusjohtajasopimuksen

BBS-Bioactive Bone Substitutes Oyj – Sisäpiiritieto: Toimitusjohtaja Juliusz Rakowski on irtisanonut toimitusjohtajasopimuksen

MFN • 18 Dec 2024 13:00

BBS-Bioactive Bone Substitutes Oyj – Muutoksia johtoryhmässä: Toimitusjohtaja Juliusz Rakowski on irtisanonut toimitusjohtajasopimuksen

MFN • 18 Dec 2024 12:00

BBS-Bioactive Bone Substitutes Oyj: Taloudellinen tiedottaminen ja yhtiökokous vuonna 2025

MFN • 13 Dec 2024 12:00

BBS-Bioactive Bone Substitutes Plc – Insider information: The results of change negotiations

MFN • 13 Dec 2024 08:30

BBS-Bioactive Bone Substitutes Plc – Insider information: BBS updates its action plans

Insider information: BBS updates its action plans

MFN • 29 Nov 2024 15:30

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Oppor...

MFN • 29 Nov 2024 15:20

BBS-Bioactive Bone Substitutes Plc: Production Director Kimmo Tyni resigns from the Company

MFN • 29 Nov 2024 14:00

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirj...

MFN • 26 Nov 2024 16:00

BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself

MFN • 22 Nov 2024 18:05

BBS-Bioactive Bone Substitutes Plc – Insider information: BBS will start change negotiations

Insider information: BBS will start change negotiations

MFN • 22 Nov 2024 18:00

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirj...

MFN • 14 Nov 2024 13:00

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirj...

MFN • 07 Nov 2024 12:00

BBS-Bioactive Bone Substitutes Plc – Insider information: The company updates the status of the CE marking process

Insider information: The company updates the status of the CE marking process

MFN • 05 Nov 2024 18:00

BBS-Bioactive Bone Substitutes Oyj on päättänyt maksuttomasta osakeannista itselleen

MFN • 23 Oct 2024 07:30

BBS-Bioactive Bone Substitutes Oyj keräsi merkintäoikeusannissa 1,45 miljoonan euron bruttovarat

MFN • 24 Sep 2024 16:00

BBS-Bioactive Bone Substitutes Oyj: Johdon liiketoimet – Oili Halonen

BBS-Bioactive Bone Substitutes Oyj: Johdon liiketoimet - Oili Halonen

MFN • 23 Sep 2024 16:00

BBS-Bioactive Bone Substitutes Oyj: Johdon liiketoimet – Jarmo Halonen

BBS-Bioactive Bone Substitutes Oyj: Johdon liiketoimet - Jarmo Halonen

MFN • 23 Sep 2024 16:00

BBS-Bioactive Bone Substitutes Oyj: Managers' Transactions - Pekka Jalovaara

MFN • 20 Sep 2024 13:00

BBS-Bioactive Bone Substitutes Oyj: Managers' Transactions - Pekka Jalovaara

MFN • 12 Sep 2024 15:00

BBS-Bioactive Bone Substitutes Oyj: ARTEBONE®-tuotteen täydentävä patentti on myönnetty USA:ssa

ARTEBONE®-tuotteen täydentävä patentti on myönnetty USA:ssa

MFN • 11 Sep 2024 14:00

BBS-Bioactive Bone Substitutes Oyj on saanut merkintäsitoumuksia ja täydentää merkintäoikeusantia koskevaa sijoitusmuistiota sekä julkistaa päivitetyn perustietoasiakirjan

EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI KOKONAISUUDESSAAN TAI OSITTAIN EIKÄ SUORAAN TAI VÄLILLISESTI YHDYSVALLOISSA, AUSTRALIASSA, KANADASSA,...

MFN • 30 Aug 2024 17:30

BBS-Bioactive Bone Substitutes Oyj: BBS järjestää enintään noin 2,4 miljoonan euron suuruisen merkintäoikeusannin

BBS järjestää enintään noin 2,4 miljoonan euron suuruisen merkintäoikeusannin

MFN • 26 Aug 2024 08:00

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirj...

MFN • 19 Aug 2024 08:00

BBS-Bioactive Bone Substitutes Oyj: ARTEBONE®:n CE-prosessin kuvaus

MFN • 16 Aug 2024 08:30

BBS-Bioactive Bone Substitutes Oyj: Puolivuosikatsaus 1.1.-30.6.2024 (tilintarkastamaton)

BBS-Bioactive Bone Substitutes Oyj: Puolivuosikatsaus 1.

MFN • 09 Aug 2024 13:00

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirj...

MFN • 22 Jul 2024 08:30

BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself

BBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself

MFN • 02 Jul 2024 12:00

BBS-Bioactive Bone Substitutes Oyj: Arvopaperimarkkinalain 9. luvun 10 pykälän mukainen ilmoitus omistusosuuden muutoksesta – Reisjärven kunta

BBS-Bioactive Bone Substitutes Oyj: Arvopaperimarkkinalain 9.

MFN • 19 Jun 2024 15:00

BBS-Bioactive Bone Substitutes Plc: Notification pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 - Finha Capital Oy

MFN • 18 Jun 2024 14:00

BBS-Bioactive Bone Substitutes Plc plans a share issue to strengthen its equity and will advance the publication date of its half-year report

BBS-Bioactive Bone Substitutes Plc plans a share issue to strengthen its equity and will advance the publication date of its half-year repor...

MFN • 18 Jun 2024 07:00

BBS-Bioactive Bone Substitutes Plc: Notification pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 - Panvest Oy

MFN • 14 Jun 2024 16:45

BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2024

MFN • 13 Jun 2024 17:00

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Oppor...

MFN • 05 Jun 2024 12:00

BBS-Bioactive Bone Substitutes Oyj: ARTEBONE®-tuotteelle tehty täydentävä patenttihakemus on hyväksytty USA:ssa

ARTEBONE®-tuotteelle tehty täydentävä patenttihakemus on hyväksytty USA:ssa

MFN • 04 Jun 2024 16:45

Kutsu BBS-Bioactive Bone Substitutes Oyj:n varsinaiseen yhtiökokoukseen

BBS-Bioactive Bone Substitutes Oyj:n osakkeenomistajat kutsutaan yhtiön varsinaiseen yhtiökokoukseen, joka pidetään yhtiön toimitiloissa oso...

MFN • 23 May 2024 16:00

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirj...

MFN • 21 May 2024 16:00

BBS-Bioactive Bone Substitutes Oyj: Yhtiökokous vuonna 2024

BBS-Bioactive Bone Substitutes Oyj:n yhtiökokous vuonna 2024

MFN • 07 May 2024 18:00

BBS-Bioactive Bone Substitutes – Insider information: The company updates the status of the CE marking process

Insider information: The company updates the status of the CE marking process

MFN • 05 May 2024 20:30

BBS-Bioactive Bone Substitutes Plc: Annastiina Kauppinen appointed as Financial Manager of BBS-Bioactive Bone Substitutes Plc

Annastiina Kauppinen appointed as Financial Manager of BBS-Bioactive Bone Substitutes Plc

MFN • 25 Apr 2024 16:00

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirj...

MFN • 24 Apr 2024 12:30

BBS-Bioactive Bone Substitutes Plc: Annual General Meeting in 2024

MFN • 17 Apr 2024 16:30

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Oppor...

MFN • 15 Apr 2024 07:00

Correction: BBS-Bioactive Bone Substitutes Plc: Annual Report for 2023 has been published

MFN • 13 Mar 2024 07:00

BBS-Bioactive Bone Substitutes Plc: Annual Report for 2023 has been published

MFN • 08 Mar 2024 13:00

Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team

GlobeNewswire • 06 Mar 2024 10:15

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023: Preparations for commercial phase initiated (unaudited)

GlobeNewswire • 26 Feb 2024 16:45

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone...

GlobeNewswire • 21 Feb 2024 09:30

BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself

GlobeNewswire • 31 Jan 2024 17:00

BBS-Bioactive Bone Substitutes Plc: Kimmo Tyni appointed as Product Director of BBS-Bioactive Bone Substitutes Plc

GlobeNewswire • 02 Jan 2024 15:30

BBS-Bioactive Bone Substitutes Plc: Merja Haikola appointed as Accountable Director (QP) of BBS-Bioactive Bone Substitutes Plc

GlobeNewswire • 27 Dec 2023 16:45

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2024

GlobeNewswire • 27 Dec 2023 16:00

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Juliusz Rakowski

GlobeNewswire • 19 Dec 2023 09:30

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Jarmo Halonen

GlobeNewswire • 19 Dec 2023 09:30

BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 1.87 million

BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 1.

GlobeNewswire • 18 Dec 2023 16:15

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions – Jarmo Halonen

GlobeNewswire • 08 Dec 2023 14:30

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions – Oili Halonen

GlobeNewswire • 08 Dec 2023 14:30

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara

GlobeNewswire • 07 Dec 2023 18:00

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara

GlobeNewswire • 04 Dec 2023 15:45

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions – Pekka Jalovaara

GlobeNewswire • 30 Nov 2023 09:00

BBS-Bioactive Bone Substitutes Plc has received new subscription undertakings and supplements the Investor Memorandum dated 24th of November 2023 relating to the rights offering and publishes updated Basic Information Document

BBS-Bioactive Bone Substitutes Plc has received new subscription undertakings and supplements the Investor Memorandum dated 24th of November...

GlobeNewswire • 26 Nov 2023 17:40

BBS-Bioactive Bone Substitutes: The Notified Body has approved the Company’s quality system

GlobeNewswire • 25 Nov 2023 10:00

BBS-Bioactive Bone Substitutes Plc publishes the Investor Memorandum and the Basic Information Document related to the Offering and information regarding Subscription undertakings

BBS-Bioactive Bone Substitutes Plc publishes the Investor Memorandum and the Basic Information Document related to the Offering and informat...

GlobeNewswire • 24 Nov 2023 07:00

CORRECTION: BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.63 million

CORRECTION: BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.

GlobeNewswire • 20 Nov 2023 18:35

CORRECTION: BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.63 million

CORRECTION: BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.

GlobeNewswire • 20 Nov 2023 17:30

BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.63 million

BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.

GlobeNewswire • 20 Nov 2023 16:03

Juliusz Rakowski starts as CEO of BBS: "My focus is already on the time after receiving the CE marking”

GlobeNewswire • 15 Nov 2023 11:50

BBS-Bioactive Bone Substitutes – Insider information: The company provides an update on the CE marking process related to the approval of the quality system – consultation with the Finnish Medicines Agency to begin on 21 November 2023

BBS-Bioactive Bone Substitutes – Insider information: The company provides an update on the CE marking process related to the approval of th...

GlobeNewswire • 02 Nov 2023 18:30

CORRECTION: Resolutions of the Extraordinary General Meeting of BBS-Bioactive Bone Substitutes Plc

GlobeNewswire • 25 Oct 2023 09:20

Resolutions of the Extraordinary General Meeting of BBS-Bioactive Bone Substitutes Plc

GlobeNewswire • 23 Oct 2023 15:30

Insider information: BBS-Bioactive Bone Substitutes Plc appoints Juliusz Rakowski as new CEO as BBS prepares for the commercial phase

GlobeNewswire • 03 Oct 2023 15:00

Correction: Notice to the BBS-Bioactive Bone Substitutes Plc’s Extraordinary General Meeting

GlobeNewswire • 28 Sep 2023 15:35

Notice to the BBS-Bioactive Bone Substitutes Plc’s Extraordinary General Meeting

GlobeNewswire • 28 Sep 2023 13:20

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Oppor...

GlobeNewswire • 15 Sep 2023 12:00

BBS-Bioactive Bone Substitutes Plc – Insider information: Plan to complete minor open issues approved – the Company updates its outlook on the schedule of the CE marking

BBS-Bioactive Bone Substitutes Plc – Insider information: Plan to complete minor open issues approved – the Company updates its outlook on t...

GlobeNewswire • 13 Sep 2023 15:45

BBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself

GlobeNewswire • 04 Sep 2023 08:45

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Oppor...

GlobeNewswire • 01 Sep 2023 14:00

BBS-Bioactive Bone Substitutes – Inside information: The final report of the additional audit received from the Notified Body

GlobeNewswire • 31 Aug 2023 12:30

BBS-Bioactive Bone Substitutes Plc: Half-Year Financial Report 1 Jan - 30 Jun 2023 (unaudited)

GlobeNewswire • 25 Aug 2023 08:00

Conversion of convertible notes pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and Riverfort Global Opportunities PCC Ltd

Conversion of convertible notes pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and Riverfort Global Opportunit...

GlobeNewswire • 17 Aug 2023 11:00

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara

GlobeNewswire • 07 Aug 2023 15:00

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Jarmo Halonen

GlobeNewswire • 07 Aug 2023 15:00

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Ahti Paananen

GlobeNewswire • 07 Aug 2023 15:00

BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 1.84 million

BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 1.

GlobeNewswire • 03 Jul 2023 12:10

BBS’ rights offering ongoing – The subscription period ends on 26 June in Sweden and 28 June in Finland

GlobeNewswire • 22 Jun 2023 08:00

BBS-Bioactive Bone Substitutes Plc: 57% of warrants 2-2022 (TO2) used for the subscription of shares, company raises EUR 162,000 in gross proceeds

BBS-Bioactive Bone Substitutes Plc: 57% of warrants 2-2022 (TO2) used for the subscription of shares, company raises EUR 162,000 in gross pr...

GlobeNewswire • 07 Jun 2023 21:30

BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.9 million

BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.

GlobeNewswire • 05 Jun 2023 08:00

BBS-Bioactive Bone Substitutes Plc – Inside information – Positive decision received on the product classification, schedule for the quality system approval to be updated

BBS-Bioactive Bone Substitutes Plc – Inside information – Positive decision received on the product classification, schedule for the quality...

GlobeNewswire • 26 May 2023 16:30

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Oppor...

GlobeNewswire • 22 May 2023 15:00

BBS-Bioactive Bone Substitutes Oyj: The subscription period for the second warrant series starts on 22 May 2023 – the subscription price is EUR 0.65 per share

BBS-Bioactive Bone Substitutes Oyj: The subscription period for the second warrant series starts on 22 May 2023 – the subscription price is ...

GlobeNewswire • 19 May 2023 11:00

BBS-Bioactive Bone Substitutes Plc: Fimea has conducted a regular periodic audit regarding the company's pharmaceutical factory permit

GlobeNewswire • 17 May 2023 18:00

Pressmeddelanden från BBS-Bioactive Bone

BBS-Bioactive Bone Substitutes Oyj hakee osakkeidensa poistamista Nasdaq First North -listalta

BBS-Bioactive Bone Substitutes Oyj: Taloudellinen tiedottaminen ja konkurssi

BBS-Bioactive Bone Substitutes Oyj - Sisäpiiritieto: BBS-Bioactive Bone Substitutes Oyj on asetettu konkurssiin

BBS-Bioactive Bone Substitutes Plc - Insider information: BBS-Bioactive Bone Substitutes Plc Files for Bankruptcy

BBS-Bioactive Bone Substitutes Oyj: Tilannetietoa yhtiön rahoitustilanteen ja toiminnan turvaamiseksi tehtävistä toimenpiteistä

BBS-Bioactive Bone Substitutes Oyj: Talouspäällikkö Annastiina Kauppinen on irtisanoutunut yhtiön palveluksesta

BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one former member of Company’s Board of Directors

Korjaus: BBS-Bioactive Bone Substitutes Oyj – Sisäpiiritieto: Toimitusjohtaja Juliusz Rakowski on irtisanonut toimitusjohtajasopimuksen

BBS-Bioactive Bone Substitutes Oyj – Muutoksia johtoryhmässä: Toimitusjohtaja Juliusz Rakowski on irtisanonut toimitusjohtajasopimuksen

BBS-Bioactive Bone Substitutes Oyj: Taloudellinen tiedottaminen ja yhtiökokous vuonna 2025

BBS-Bioactive Bone Substitutes Plc – Insider information: The results of change negotiations

BBS-Bioactive Bone Substitutes Plc – Insider information: BBS updates its action plans

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc: Production Director Kimmo Tyni resigns from the Company

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself

BBS-Bioactive Bone Substitutes Plc – Insider information: BBS will start change negotiations

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Plc – Insider information: The company updates the status of the CE marking process

BBS-Bioactive Bone Substitutes Oyj on päättänyt maksuttomasta osakeannista itselleen

BBS-Bioactive Bone Substitutes Oyj keräsi merkintäoikeusannissa 1,45 miljoonan euron bruttovarat

BBS-Bioactive Bone Substitutes Oyj: Johdon liiketoimet – Oili Halonen

BBS-Bioactive Bone Substitutes Oyj: Johdon liiketoimet – Jarmo Halonen

BBS-Bioactive Bone Substitutes Oyj: Managers' Transactions - Pekka Jalovaara

BBS-Bioactive Bone Substitutes Oyj: Managers' Transactions - Pekka Jalovaara

BBS-Bioactive Bone Substitutes Oyj: ARTEBONE®-tuotteen täydentävä patentti on myönnetty USA:ssa

BBS-Bioactive Bone Substitutes Oyj on saanut merkintäsitoumuksia ja täydentää merkintäoikeusantia koskevaa sijoitusmuistiota sekä julkistaa päivitetyn perustietoasiakirjan

BBS-Bioactive Bone Substitutes Oyj: BBS järjestää enintään noin 2,4 miljoonan euron suuruisen merkintäoikeusannin

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: ARTEBONE®:n CE-prosessin kuvaus

BBS-Bioactive Bone Substitutes Oyj: Puolivuosikatsaus 1.1.-30.6.2024 (tilintarkastamaton)

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself

BBS-Bioactive Bone Substitutes Oyj: Arvopaperimarkkinalain 9. luvun 10 pykälän mukainen ilmoitus omistusosuuden muutoksesta – Reisjärven kunta

BBS-Bioactive Bone Substitutes Plc: Notification pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 - Finha Capital Oy

BBS-Bioactive Bone Substitutes Plc plans a share issue to strengthen its equity and will advance the publication date of its half-year report

BBS-Bioactive Bone Substitutes Plc: Notification pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 - Panvest Oy

BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2024

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Oyj: ARTEBONE®-tuotteelle tehty täydentävä patenttihakemus on hyväksytty USA:ssa

Kutsu BBS-Bioactive Bone Substitutes Oyj:n varsinaiseen yhtiökokoukseen

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Oyj: Yhtiökokous vuonna 2024

BBS-Bioactive Bone Substitutes – Insider information: The company updates the status of the CE marking process

BBS-Bioactive Bone Substitutes Plc: Annastiina Kauppinen appointed as Financial Manager of BBS-Bioactive Bone Substitutes Plc

BBS-Bioactive Bone Substitutes Oyj: BBS:n ja Riverfort Global Opportunities PCC Ltd:n väliseen rahoitusjärjestelyyn liittyvä vaihtovelkakirjalainojen vaihtaminen osakkeiksi

BBS-Bioactive Bone Substitutes Plc: Annual General Meeting in 2024

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Oyj: Verkkosivujen toiminta palautettu

BBS-Bioactive Bone Substitutes Plc: Annual General Meeting in 2024

BBS-Bioactive Bone Substitutes Plc: The website is under attack

Correction: BBS-Bioactive Bone Substitutes Plc: Annual Report for 2023 has been published

BBS-Bioactive Bone Substitutes Plc: Annual Report for 2023 has been published

Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023: Preparations for commercial phase initiated (unaudited)

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position

BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself

BBS-Bioactive Bone Substitutes Plc: Kimmo Tyni appointed as Product Director of BBS-Bioactive Bone Substitutes Plc

BBS-Bioactive Bone Substitutes Plc: Merja Haikola appointed as Accountable Director (QP) of BBS-Bioactive Bone Substitutes Plc

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2024

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Juliusz Rakowski

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Jarmo Halonen

BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 1.87 million

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions – Jarmo Halonen

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions – Oili Halonen

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions – Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc has received new subscription undertakings and supplements the Investor Memorandum dated 24th of November 2023 relating to the rights offering and publishes updated Basic Information Document

BBS-Bioactive Bone Substitutes: The Notified Body has approved the Company’s quality system

BBS-Bioactive Bone Substitutes Plc publishes the Investor Memorandum and the Basic Information Document related to the Offering and information regarding Subscription undertakings

CORRECTION: BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.63 million

CORRECTION: BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.63 million

BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.63 million

Juliusz Rakowski starts as CEO of BBS: "My focus is already on the time after receiving the CE marking”

BBS-Bioactive Bone Substitutes – Insider information: The company provides an update on the CE marking process related to the approval of the quality system – consultation with the Finnish Medicines Agency to begin on 21 November 2023

CORRECTION: Resolutions of the Extraordinary General Meeting of BBS-Bioactive Bone Substitutes Plc

Resolutions of the Extraordinary General Meeting of BBS-Bioactive Bone Substitutes Plc